Site search

Clear filter
2898 results for '' found
Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascul
Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascul
/
A Pilot Study of Post Operative Iron Infusion for the Treatment of Anaemia in trauma Patients (ACTRN12624000410550)
/
Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)
Extending the time window for Tenecteplase by Effective RecanalizatioN of bAsilar artery occLusion in patients with POSTerior circulation stroke (NCT05105633)
/
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Imatinib Combined with Chemotherapy in Patients with Newly Diagnosed
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Imatinib Combined with Chemotherapy in Patients with Newly Diagnosed
/
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients with SDH-Deficient Gastrointestinal Stromal Tumor [POLARIS-3] (NCT06640361)
/
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
/
PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
/
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
/
A Proof Of Concept study to evaluate the sensitivity and specificity of Wearables and Algorithm Technology for Chronic Heart Disease for improved diagnosis of Heart Failure (ACTRN12623000038695)
/
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
/
26 27 28 29 30